Skip to main content
Premium Trial:

Request an Annual Quote

Philips Inks Oncology Deals With Memorial Sloan Kettering, Intermountain, Illumina

CHICAGO (GenomeWeb) – With the annual American Society of Clinical Oncology meeting set to open here Friday, Royal Philips has announced two deals aimed at advancing precision medicine in cancer care.

Amsterdam-based Philips is joining with Navican, a genomic testing and research company spun out of Utah's Intermountain Healthcare in October, to offer end-to-end precision oncology services to other health systems. The partners will integrate Navican's TheraMap services with the Philips IntelliSpace Genomics platform; the latter already incorporates Illumina next-generation sequencing technology.

"Through this joint approach we are bringing together the latest technologies with the aim to provide community hospitals and treatment centers worldwide with the opportunity to implement Intermountain’s best practice in precision medicine into their everyday care practices," Lincoln Nadauld, executive director of Intermountain Precision Genomics, said in a statement.

Philips also said today that it has entered into a research partnership with Memorial Sloan Kettering Cancer Center in New York. The partnership also will lean on IntelliSpace, in this case to develop precision diagnostics specifically for pancreatic cancer.

The focus there will be on resolving single cell-level differences within and between tumors, according to Philips.

"Our collaboration with Philips will allow rapid advances in understanding the clinically significant aspects of intratumoral heterogeneity within and between patients and how to take full advantage of this knowledge for the benefit of the patient," Christine Iacobuzio-Donahue, associate director for translational research at MSK's David M. Rubenstein Center for Pancreatic Research, said in a separate statement.